Caredx Inc (CDNA) Stock Price, Quote & News

Company Profile

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. T...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 415 287 2300

Fax: 415 287 2450

Website: caredx.com

Address:

8000 Marina Boulevard, Brisbane, United States

OfficialStocktwitsUser Feb. 20 at 6:34 PM

$CDNA RSI: 40.68, MACD: -0.0552 Vol: 0.72, MA20: 19.94, MA50: 19.73 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

CapitalParagon Feb. 20 at 2:01 PM

$CDNA CareDx provides transplant diagnostic solutions. Growth depends on procedure volumes. Reimbursement stability supports margins.

0 · Reply

ZacksResearch Feb. 16 at 5:11 PM

$CDNA ripping higher on a data win in AML & MDS. 🚀 AlloHeme showed early relapse detection in AML and MDS post HCT, fueling the stock’s move and supporting Transplant+ expansion into cell therapy markets. That’s a meaningful validation signal. See what this could mean for CareDx’s growth story 👉 https://www.zacks.com/stock/news/2869883/caredx-reports-positive-data-for-alloheme-in-aml-and-mds-post-hct?cid=sm-stocktwits-2-2869883-teaser-33699&ADID=SYND_STOCKTWITS_TWEET_2_2869883_TEASER_33699

0 · Reply

ZacksResearch Feb. 16 at 4:11 PM

$CDNA surged 65.6% in 6 months — is AlloHeme the key? 🚀 The new blood-based test detects AML/MDS relapse a median of 41 days earlier, with 85% sensitivity and 92% specificity, according to the ACROBAT study. This positions CDNA for growth in cell therapy and hematologic oncology. See what makes the investment case strong for CDNA 👉 https://www.zacks.com/stock/news/2869883/caredx-reports-positive-data-for-alloheme-in-aml-and-mds-post-hct?cid=sm-stocktwits-2-2869883-body-33678&ADID=SYND_STOCKTWITS_TWEET_2_2869883_BODY_33678

0 · Reply

GoldenTicket1 Feb. 13 at 2:59 PM

$CDNA. CareDx Expands “Transplant Plus” Into Cell Therapy, Showcases AlloHeme AML/MDS Relapse Data https://finance.yahoo.com/news/caredx-expands-transplant-plus-cell-060902356.html

0 · Reply

GoldenTicket1 Feb. 13 at 2:58 PM

$CDNA CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy https://finance.yahoo.com/news/caredx-announces-clinical-validation-results-120500166.html

0 · Reply

DARKP00L Feb. 12 at 12:39 PM

$CDNA 07:14 on Feb. 12 2026 CareDx Announced Pivotal Clinical Validation Results Of AlloHeme, A Non-invasive, Next‑generation Sequencing-based, And AI-powered Monitoring Test Designed To Predict Relapse In Patients With Acute Myeloid Leukemia And Myelodysplastic Syndromes Following Allogeneic Hematopoietic Cell Transplant #tradeideas

0 · Reply

11thestate Feb. 11 at 4:17 PM

Imagine buying $CDNA at its peak, only to watch it crash like this — and then finding out there’s a way to get some money back. To all $CDNA investors out there, we’ve got some important news for you: https://11th.com/cases/caredx-investor-settlement

0 · Reply

SamCo1 Feb. 5 at 1:53 PM

$CDNA any news?

1 · Reply

GoldenTicket1 Feb. 4 at 9:44 PM

$CDNA Both scam accounts created on the same day. Click on the accounts for yourself. 🤡

0 · Reply

CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference

Feb 15, 2026, 6:08 PM EST - 4 days ago

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells

ABT ALKT CWAN DKNG DT ESTA EXAS

Feb 12, 2026, 4:24 PM EST - 7 days ago

CareDx, Inc. (CDNA) Discusses AlloHeme Clinical Validation Data Review and Launch Timeline in AML and MDS Post-Cell Therapy Transcript

Feb 12, 2026, 7:05 AM EST - 8 days ago

CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy

Feb 10, 2026, 4:01 PM EST - 9 days ago

CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Feb 3, 2026, 7:05 AM EST - 17 days ago

CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings

Jan 27, 2026, 4:05 PM EST - 23 days ago

CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 12, 2026, 7:05 AM EST - 5 weeks ago

CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Jan 7, 2026, 7:05 AM EST - 6 weeks ago

CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response

TXG

Dec 26, 2025, 4:05 PM EST - 7 weeks ago

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 18, 2025, 5:00 PM EST - 2 months ago

CareDx Provides Notice of Proposed Derivative Settlement

Nov 24, 2025, 4:05 PM EST - 3 months ago

SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation

Nov 10, 2025, 8:00 AM EST - 3 months ago

CareDx to Participate in Upcoming Investor Conferences

Nov 6, 2025, 8:00 AM EST - 3 months ago

CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025

Nov 4, 2025, 10:16 PM EST - 3 months ago

CareDx, Inc (CDNA) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:05 PM EST - 3 months ago

CareDx Announces Third Quarter 2025 Financial Results

Oct 27, 2025, 7:05 AM EDT - 4 months ago

CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

Oct 23, 2025, 4:05 PM EDT - 4 months ago

CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart Failure

Oct 22, 2025, 4:01 PM EDT - 4 months ago

CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors

Oct 21, 2025, 8:00 AM EDT - 4 months ago

CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025

Oct 6, 2025, 7:05 AM EDT - 4 months ago

CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE® at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting

Sep 2, 2025, 4:01 PM EDT - 6 months ago

CareDx Issues Comment Letter on Draft LCD Policy

Aug 26, 2025, 1:08 PM EDT - 6 months ago

CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential

Aug 21, 2025, 4:01 PM EDT - 6 months ago

CareDx to Participate in Wells Fargo Healthcare Conference

Aug 6, 2025, 10:47 PM EDT - 7 months ago

CareDx, Inc (CDNA) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:57 PM EDT - 7 months ago

CareDx Announces Appointment of Nathan Smith as Chief Financial Officer

Aug 6, 2025, 4:01 PM EDT - 7 months ago

CareDx Announces Second Quarter 2025 Financial Results

Aug 6, 2025, 12:56 PM EDT - 7 months ago

CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation

Jul 31, 2025, 4:01 PM EDT - 7 months ago

CareDx Announces Landmark Data in AI-Powered Transplant Diagnostics Showcased in Over 40 Abstracts and 16 Oral Presentations at the 2025 World Transplant Congress

Jul 23, 2025, 7:05 AM EDT - 7 months ago

CareDx to Report Second Quarter 2025 Financial Results

Jul 18, 2025, 8:00 AM EDT - 7 months ago

CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection

Jun 14, 2025, 7:23 AM EDT - 8 months ago

CareDx: The Transplant Diagnostics Leader, But Challenges Will Increase On The Road Ahead

Jun 3, 2025, 4:30 PM EDT - 9 months ago

CareDx Announces Repurchase of 5% of Outstanding Shares

Apr 30, 2025, 8:39 PM EDT - 10 months ago

CareDx, Inc (CDNA) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 4:05 PM EDT - 10 months ago

CareDx Reports First Quarter 2025 Results

Apr 29, 2025, 7:05 AM EDT - 10 months ago

CareDx Announces New Data on AlloSure Lung Presented at 2025 International Society for Heart and Lung Transplantation Meeting

Apr 24, 2025, 7:05 AM EDT - 10 months ago

CareDx Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transplantation Meeting

Apr 21, 2025, 4:01 PM EDT - 10 months ago

CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Apr 8, 2025, 7:05 AM EDT - 11 months ago

CareDx to Report First Quarter 2025 Financial Results

Mar 28, 2025, 6:07 PM EDT - 11 months ago

CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA

Mar 20, 2025, 7:00 AM EDT - 1 year ago

CI Global Asset Management Announces Securityholder Approval of Fund Mergers

Mar 14, 2025, 10:50 PM EDT - 1 year ago

CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA

Mar 11, 2025, 7:05 AM EDT - 1 year ago

CareDx Launches Two Expanded Indications for AlloSure Testing Services

Feb 26, 2025, 10:01 PM EST - 1 year ago

CareDx, Inc (CDNA) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 1 year ago

CareDx Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 25, 2025, 7:05 AM EST - 1 year ago

CareDx Announces District Court Reverses Jury Decision in Patent Infringement Case Overturning Prior $96 Million Verdict

Feb 20, 2025, 7:05 AM EST - 1 year ago

CareDx Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients

Feb 13, 2025, 7:05 AM EST - 1 year ago

CareDx Announces Presentation of Data at 2025 Tandem Meetings Demonstrating Strong Performance of AlloHeme in Early Relapse Detection for Hematologic Malignancies

Feb 11, 2025, 7:05 AM EST - 1 year ago

CareDx to Report Fourth Quarter and Full Year 2024 Financial Results

Feb 10, 2025, 2:08 PM EST - 1 year ago

Final Trades: NRG Energy, MP Materials, CareDx and Applovin

APP MP NRG

OfficialStocktwitsUser Feb. 20 at 6:34 PM

0 · Reply

CapitalParagon Feb. 20 at 2:01 PM

$CDNA CareDx provides transplant diagnostic solutions. Growth depends on procedure volumes. Reimbursement stability supports margins.

0 · Reply

ZacksResearch Feb. 16 at 5:11 PM

0 · Reply

ZacksResearch Feb. 16 at 4:11 PM

0 · Reply

GoldenTicket1 Feb. 13 at 2:59 PM

$CDNA. CareDx Expands “Transplant Plus” Into Cell Therapy, Showcases AlloHeme AML/MDS Relapse Data https://finance.yahoo.com/news/caredx-expands-transplant-plus-cell-060902356.html

0 · Reply

GoldenTicket1 Feb. 13 at 2:58 PM

0 · Reply

DARKP00L Feb. 12 at 12:39 PM

0 · Reply

11thestate Feb. 11 at 4:17 PM

0 · Reply

SamCo1 Feb. 5 at 1:53 PM

$CDNA any news?

1 · Reply

GoldenTicket1 Feb. 4 at 9:44 PM

$CDNA Both scam accounts created on the same day. Click on the accounts for yourself. 🤡

0 · Reply

BondHarbor Feb. 4 at 3:11 PM

$CDNA is a molecular diagnostics company focused on organ transplant rejection; its growth depends on clinical adoption and favorable reimbursement for its proprietary tests.

0 · Reply

BullionBeaconry Feb. 4 at 2:29 PM

$CDNA is a molecular diagnostics company focused on organ transplant rejection; its growth depends on clinical adoption and reimbursement for its tests.

0 · Reply

GoldenTicket1 Feb. 3 at 9:24 PM

Does CareDx's 10x Genomics Deal and CEO Share Sales Reframe Its Precision Medicine Story? $CDNA - Simply Wall St https://stocks.apple.com/ATvuOsTfgTrKZGXoZg1uU0g

0 · Reply

GoldenTicket1 Feb. 3 at 3:21 PM

$CDNA Source: The Journal of Heart and Lung Transplantation https://share.google/tM5oROD8IUWz1AeOv

0 · Reply

GoldenTicket1 Feb. 3 at 2:56 PM

$CDNA BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that pivotal clinical validation data from the ACROBAT study (NCT04635384) will be presented at the 2026 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, held February 4-7, 2026, in Salt Lake City, Utah. https://share.google/HLioHGzppUvK9VLL8

0 · Reply

SharonTerry971 Feb. 3 at 1:02 PM

$CDNA $PSFE Speculative pairing

0 · Reply

DARKP00L Feb. 3 at 12:19 PM

$CDNA 07:10 on Feb. 03 2026 CareDx To Present Pivotal Clinical Validation Data From ACROBAT Study At 2026 Tandem Meetings, Transplantation & Cellular Therapy Meetings Of ASTCT And CIBMTR #tradeideas

0 · Reply

11thestate Jan. 30 at 1:06 PM

If you missed the deadline, don’t miss this update. This is probably the most useful info you’ve read in years about $CDNA — how you can actually recover something: https://11th.com/cases/caredx-investor-settlement

0 · Reply

GoldenTicket1 Jan. 27 at 11:10 PM

BRISBANE, Calif., January 27, 2026--(BUSINESS WIRE)--CareDx, Inc. Nasdaq: $CDNA - The Transplant Company™ —, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT on Tuesday, February 10, 2026. https://finance.yahoo.com/news/caredx-participate-btig-13th-annual-210500129.html

0 · Reply

GoldenTicket1 Jan. 23 at 12:28 AM

$CDNA

0 · Reply

11thestate Jan. 21 at 3:58 PM

0 · Reply

BillionerOfKing Jan. 15 at 10:25 PM

$CDNA Current Stock Price: $20.57 Contracts to trade: $20 CDNA Jan 16 2026 Call Entry: $0.50 Exit: $0.85 ROI: 71% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Market Cap	1.03B
Revenue (ttm)	333.79M
Net Income (ttm)	52.55M
EPS (ttm)	N/A
PE Ratio	16.34
Forward PE	N/A
Profit Margin	15.74%
Debt to Equity Ratio	0.00

Volume	223,286
Avg Vol	736,522
Day's Range	N/A - N/A
Shares Out	51.43M
Stochastic %K	61%
Beta	2.51
Analysts	Sell
Price Target	$23.60